After filing hitch, Eisai and Biogen begin rolling FDA submission for subcutaneous Leqembi
Fierce Pharma
MAY 14, 2024
regulators last month, Eisai and Biogen’s effort to deploy a more convenient version of their Alzheimer’s disease drug Leqembi appears to be back on track. After suffering a setback with U.S.
Let's personalize your content